<DOC>
	<DOCNO>NCT02762812</DOCNO>
	<brief_summary>BCD-055-2 international multi-center comparative double-blind randomize clinical trial evaluate efficacy safety BCD-055 ( JSC `` BIOCAD '' , Russia ) Remicade® patient ankylose spondylitis . BCD-055 biosimilar infliximab ( JSC `` BIOCAD '' , Russia )</brief_summary>
	<brief_title>Comparative Clinical Trial Evaluate Efficacy Safety BCD-055 Remicade® Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Signed informed consent Active ankylosing spondylitis accord modify criteria New York classification ( 1984 ) , diagnose least 3 month prior screen . Active disease accord BASDAI ( score 4 ) nonsteroidal antiinflammatory drug use last 3 month prior screen . Mean backache intensity equal 4 point . Previous therapy ankylose spondylitis monoclonal antibody ( include tumor necrosis factor ) Total spinal ankylosis History tuberculosis Body mass 120 kg Patient take corticosteroid 4 week dose 10 mg ( recalculate prednisolone ) signing informed consent . Prior use diseasemodifying antirheumatic drug include methotrexate , sulfasalazin , chloroquine hydroxychloroquine 4 week randomization . Prior use alkylating agent 12 month prior sign inform consent . Intraarticular use corticosteroid 4 week randomization . Prior use live attenuate vaccine 8 week sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>